{"url_path":"/sec/ser/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000035-index.html","accession_number":"0001708599-26-000035","cik":"0001708599","ticker":"SER","issuer_name":"Serina Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000035-index.html","primary_entity_key":"0001708599","primary_entity_name":"Serina Therapeutics, Inc."},"word_count":53,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nCertain Trading Arrangements\n\nDuring the three months ended March 31, 2026, none of the directors or officers of the Company, adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of SEC Regulation S-K.\n\n36\n\n[Table of Contents](#i6128db602b644f7faf6d05e37f43917b_7)"}